Enlivex Therapeutics Ltd. (1BT.F)

1.2000 +0.0300 (+2.56%) At close: 08:02AM CEST

Enlivex Therapeutics Ltd.

14 Einstein Street
Ness Ziona 7403618
Israel
972 2 670 8072
https://www.enlivex.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Description

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Corporate Governance

Enlivex Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.